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Abstract
Background: Both apolipoprotein (Apo) C-III gene polymorphism and alcohol consumption have been associated
with increased serum triglyceride (TG) levels, but their interactions on serum TG levels are not well known. The
present study was undertaken to detect the interactions of the ApoC-III 3238C>G (rs5128) polymorphism and
alcohol consumption on serum TG levels.
Methods: A total of 516 unrelated nondrinkers and 514 drinkers aged 15-89 were randomly selected from our
previous stratified randomized cluster samples. Genotyping of the ApoC-III 3238C>G was performed by polymerase
chain reaction and restriction fragment length polymorphism combined with gel electrophoresis, and then
confirmed by direct sequencing. Interactions of the ApoC-III 3238C>G genotype and alcohol consumption was
assessed by using a cross-product term between genotypes and the aforementioned factor.
Results: Serum total cholesterol (TC), TG, high-density lipoprotein cholesterol (HDL-C), ApoA-I and ApoB levels
were higher in drinkers than in nondrinkers (P < 0.05-0.001). There was no significant difference in the genotypic
and allelic frequencies between the two groups. Serum TG levels in nondrinkers were higher in CG genotype than
in CC genotype (P < 0.01). Serum TC, TG, low-density lipoprotein cholesterol (LDL-C) and ApoB levels in drinkers
were higher in GG genotype than in CC or CG genotype (P < 0.01 for all). Serum HDL-C levels in drinkers were
higher in CG genotype than in CC genotype (P < 0.01). Serum TC, TG, HDL-C and ApoA-I levels in CC genotype,
TC, HDL-C, ApoA-I levels and the ratio of ApoA-I to ApoB in CG genotype, and TC, TG, LDL-C, ApoA-I and ApoB
levels in GG genotype were higher in drinkers than in nondrinkers (P < 0.05-0.01). But the ratio of ApoA-I to ApoB
in GG genotype was lower in drinkers than in nondrinkers (P < 0.01). Multivariate logistic regression analysis
showed that the levels of TC, TG and ApoB were correlated with genotype in nondrinkers (P < 0.05 for all). The
levels of TC, LDL-C and ApoB were associated with genotype in drinkers (P < 0.01 for all). Serum lipid parameters
were also correlated with age, sex, alcohol consumption, cigarette smoking, blood pressure, body weight, and
body mass index in both groups.
Conclusions: This study suggests that the ApoC-III 3238CG heterozygotes benefited more from alcohol
consumption than CC and GG homozygotes in increasing serum levels of HDL-C, ApoA-I, and the ratio of ApoA-I
to ApoB, and lowering serum levels of TC and TG.
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Coronary artery disease (CAD) is the most common
cause of death in industrialized countries with evidence
that high plasma or serum triglyceride (TG) concentra-
tion is an independent risk factor [1-5]. It is well known
that plasma TG concentration is modulated by both
environmental and genetic factors [6]. Numerous studies
have evaluated the influence of alcohol intake, an index
of lifestyle, on plasma lipid and lipoprotein concentra-
tions. Alcohol consumption can promote lipogenesis [7]
and accordingly increase serum TG levels [8,9]. Alcohol
in doses > 30 g/day in both sexes can augment the TG
level. It has been found that the alcohol intake of 60 g/
day increases the TG level by about 0.19 mg/dl per 1
gram of alcohol consumed [10].
Plasma apolipoprotein (Apo) C-III is a major compo-
nent of TG-rich lipoproteins (chylomicrons and very
low density lipoprotein) and a minor component of high
density lipoprotein. The mature 79-amino-acid ApoC-III
protein is synthesized predominantly in the liver but
also to a lesser extent in the intestine. In vitro studies
have indicated that ApoC-III is a noncompetitive inhibi-
tor of lipoprotein lipase, thereby suggesting an impor-
tant role in the catabolism of TG-rich lipoproteins [11].
Plasma ApoC-III concentrations were positively corre-
lated with plasma TG levels, both in the normal popula-
tion as well as in hypertriglyceridemic patients [12] or
in transgenic animals [13]. ApoC-III gene has been
mapped to chromosome 11q23.3 [14] and is flanked by
the genes for ApoA-I and ApoA-IV in a 15-kb gene
cluster [15]. Several polymorphic sites have been
detected within and around the ApoC-III gene. The
most extensively studied is the SstI polymorphism, due
to a C®G substitution at nucleotide 3238, in the 3′
untranslated region of the gene. Numerous studies have
found an association between the presence of a poly-
morphic SstI site in the untranslated region of the
ApoC-III gene with raised ApoC-III and TG concentra-
tions [16-53] and with an increased risk of CAD
[53-62]. However, little is known about the interactions
o ft h eA p o C - I I Ig e n ep o l y m o r p h i s ma n da l c o h o lc o n -
sumption on serum lipid concentrations. Therefore, the
aim of the present study was to determine the interac-
tions of the ApoC-III 3238C>G (rs5128) polymorphism
and alcohol consumption on serum lipid levels.
Materials and methods
Study subjects
A total of 1030 unrelated subjects who reside in 16 vil-
lages in Napo County, Guangxi Zhuang Autonomous
Region, People’s Republic of China were randomly
selected from our previous stratified randomized cluster
samples [63]. The age of the subjects ranged from 15 to
89 years, with an average age of 43.30 ± 17.69 years.
There were 516 nondrinkers and 514 drinkers. All of
the subjects were peasants. The study subjects were
essentially healthy and had no evidence of diseases
related to atherosclerosis, CAD and diabetes. None of
them had been treated with b-adrenergic blocking
agents and lipid-lowering drugs such as statins or
fibrates. The present study was approved by the Ethics
Committee of the First Affiliated Hospital, Guangxi
Medical University. Informed consent was obtained
from all subjects after they received a full explanation of
the study.
Epidemiological survey
The survey was carried out using internationally stan-
dardized methods, following a common protocol. Infor-
mation on demographics, socioeconomic status, and
lifestyle was collected with standardized questionnaires.
Smoking status was categorized into groups of cigarettes
per day: <20 and ≥20. Alcohol consumption was cate-
gorized into groups of grams of alcohol per day: ≤25
and >25. The physical examination included blood pres-
s u r e ,b o d yh e i g h t ,a n db o d yw e i g h t ,a n db o d ym a s s
index (BMI) was calculated as weight (kg) divided by
height (m) squared. Sitting blood pressure was measured
three times with use of a mercury sphygmomanometer
after the subjects had a 5-minute rest, and the average
of the three measurements was used in statistical analy-
sis. Systolic blood pressure was determined by the first
Korotkoff sound, and diastolic blood pressure by the
fifth Korotkoff sound.
Biochemical analysis
Venous blood samples (8 ml) were drawn from a fore-
arm vein of every subject after venous occlusion for a
few seconds in a sitting position, after an overnight fast
of 12 h and abstention from alcohol use for at least
12 h. A part of the sample (3 ml) was collected into
glass tubes and allowed to clot at ambient temperature,
and used to determine serum lipid levels, and another
part of the sample (5 ml) was transferred into tubes
with anticoagulate solution (4.80 g/L citric acid, 14.70 g/L
glucose, and 13.20 g/L tri-sodium citrate) and used to
extract deoxyribonucleic acid (DNA). Immediately follow-
ing clotting serum was separated by centrifugation for 15
minutes at 3000 rpm. The levels of serum total cholesterol
(TC), TG, high-density lipoprotein cholesterol (HDL-C),
and low-density lipoprotein cholesterol (LDL-C) in sam-
ples were determined by enzymatic methods with com-
mercially available kits, Tcho-1, TG-LH (RANDOX
Laboratories Ltd., Ardmore, Diamond Road, Crumlin Co.
Antrim, United Kingdom, BT29 4QY), Cholestest N HDL,
and Cholestest LDL (Daiichi Pure Chemicals Co., Ltd.,
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levels were assessed by the immunoturbidimetric immu-
noassay using a commercial kit (RANDOX Laboratories
Ltd.). All determinations were performed with an autoana-
lyzer (Type 7170A; Hitachi Ltd., Tokyo, Japan) in the Clin-
ical Science Experiment Center of the First Affiliated
Hospital, Guangxi Medical University.
DNA amplification and genotyping
Total genomic DNA was isolated from peripheral
blood leukocytes using the phenol-chloroform method.
The extracted DNA was stored at 4°C until analysis.
Genotyping of the ApoC-III 3238C>G was performed
by polymerase chain reaction and restriction fragment
length polymorphism (PCR-RFLP) according to the
previous reports [19]. The sequence of the forward and
backward primers used was 5′-CACTAGCCCAGAGA-
GAGGAGTGCC-3′ and 5′-CTGAGCCCAGCCGCA-
CACTAA-3′ (Sangon, Shanghai, China). Each reaction
system of a total volume of 25 μL, comprised 0.2 μgo f
genomic DNA; 1.0 μL of each primer (10 pmol/μl);
2.5 μL of 10 × buffer solution; 1.5 μLo fM g C l 2
(25 mmol/L); 2.0 μLo fd N T P( 2 . 5m m o l / L ) ;a n d1 . 5U
of Taq polymerase (Takara). For the amplification,
initial denaturation at 94°C for 5 minutes was followed
by 30 cycles of denaturation at 94°C for 30 s, annealing
at 61°C for 30 s, and extension at 72°C for 45 s, with
final extension at 72°C for 4 min. Each restriction
enzyme reaction was performed with 8 μL of amplified
DNA; 2 μLo f1 0×b u f f e rs o l u t i o n ;a n d0 . 2USstI
restriction ezyme in a total volume of 25 μLd i g e s t e d
at 64°C for 4 h. The digestive products were separated
by electrophoresis on 2% sepharose gel for 60 min.
The length of each digested DNA fragment was deter-
mined by comparing migration of a sample with that
of standard DNA marker. Stained with ethidium bro-
mide, the gel was visualized under ultraviolet light and
photographed. Genotypes were scored by an experi-
enced reader blinded to epidemiological and lipid
results.
DNA sequencing
Six samples (CC, CG and GG genotypes in two, respec-
tively) detected by the PCR-RFLP were also confirmed
by direct sequencing. The PCR product was purified by
low melting point gel electrophoresis and phenol extrac-
tion, and then the DNA sequence were analyzed by
using an ABI Prism 3100 (Applied Biosyatems) in
Shanghai Sangon Biological Engineering Technology &
Services Co., Ltd., People’s Republic of China.
Diagnostic criteria
The normal values of serum TC, TG, HDL-C, LDL-C,
ApoA-I, and ApoB in our Clinical Science Experiment
Center were 3.10-5.17, 0.56-1.70, 1.04-1.81, 1.70-3.37
mmol/L, 1.20-1.60, and 0.63-1.14 g/L; respectively
[63]. Hypertension was diagnosed according to the cri-
teria of 1999 The World Health Organization-Interna-
tional Society of Hypertension Guidelines for the
management of hypertension [64]. The diagnostic cri-
teria of overweight and obesity were according to the
Cooperative Meta-analysis Group of China Obesity
Task Force. Normal weight, overweight and obesity
were defined as a BMI <24, 24-28, and >28 kg/m
2,
respectively [63,64].
Statistical analysis
Epidemiological data were recorded on a pre-designed
form and managed with Excel software. The quantitative
variables were presented as mean ± standard deviation
(serum TG levels were presented as medians and inter-
quartile ranges). The difference in general characteristics
between nondrinkers and drinkers was tested by the
Student’su n p a i r e dt test. The allele frequencies of the
ApoC-III 3238C>G were determined by gene counting.
A chi-square analysis was used to evaluate the allelic
and genotypic frequencies that were calculated from the
observed genotypic counts and to assess Hardy-Wein-
berg expectations. Interaction between the ApoC-III
3238C>G genotype and alcohol consumption was
assessed by using a cross-product term between geno-
types and the aforementioned factor. Statistical signifi-
cance was evaluated with analysis of covariance
(ANCOVA). The co-variables include sex, age, BMI,
hypertension, and cigarette smoking. In order to evalu-
ate the association of serum lipid parameters with sev-
eral environmental factors and genotypes, unconditional
logistic regression analysis was also performed in the
combined population, nondrinkers, and drinkers; respec-
tively. The statistical analyses were performed with the
statistical software package SPSS 13.0 (SPSS Inc., Chi-
cago, Illinois). A P value of less than 0.05 was consid-
ered statistically significant.
Results
General characteristics between nondrinkers and drinkers
Table 1 gives the general characteristics between the
nondrinkers and drinkers. The ratio of male to female,
the mean age, the levels of systolic blood pressure, dia-
stolic blood pressure and pulse pressure, and the per-
centages of subjects who smoked cigarettes were higher
in drinkers than in nondrinkers (P < 0.05-0.001). There
was no significant difference in the BMI between the
two groups (P > 0.05).
Serum lipid levels between nondrinkers and drinkers
The levels of TC, TG, HDL-C, ApoA-I and ApoB were
higher in drinkers than in nondrinkers (P < 0.05-0.001).
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LDL-C and the ratio of ApoA-I to ApoB between the
two groups (P > 0.05 for each).
Results of electrophoresis and genotyping
After the genomic DNA of the samples was amplified by
PCR and imaged by 2% agarose gel electrophoresis, the
purpose gene of 596 bp nucleotide sequences could be
seen in the samples (Figure 1). The genotypes identified
were named according to the presence or absence of the
enzyme restriction sites, when a C to G transversion at
nucleotide position 3238 of the ApoC-III gene. The pre-
sence of the cutting site indicates the 3238G allele,
while its absence indicates the 3238C allele. Thus, the
GG genotype is homozygote for the presence of the site
(bands at 371 bp and 225 bp), CG genotype is heterozy-
gote for the presence and absence of the site (bands at
596 bp, 371 bp and 225 bp), and CC genotype is homo-
zygote for the absence of the site (band 596 bp; Figure
1). The genotype distribution was consistent with the
Hardy-Weinberg equilibrium.
Results of sequencing
The results shown as CC, CG and GG genotypes by
PCR-RFLP, CC, CG and GG genotypes were also con-
firmed by sequencing (Figure 2).
Genotypic and allelic frequencies
The genotypic and allelic frequencies of the ApoC-III
3238C>G are shown in Table 2. The frequencies of CC,
CG and GG genotypes were 45.7%, 43.0% and 11.3% in
nondrinkers, and 45.2%, 45.5% and 9.3% in drinkers
(P > 0.05); respectively. The frequencies of C and G
alleles were 67.2% and 32.8% in nondrinkers, and 67.9%
and 32.1% in drinkers (P > 0.05); respectively.
Genotypes and serum lipid levels
As shown in Table 3, the levels of TG in nondrinkers
were higher in CG genotype than in CC genotype (P <
0.01), and the ratio of ApoA-I to ApoB in nondrinkers
was higher in GG genotype than in CG genotype (P <
0.05).
The levels of TC, TG, LDL-C and ApoB in drinkers
were higher in GG genotype than in CC or CG geno-
type (P < 0.01 for all). The levels of HDL-C in drinkers
were higher in CG genotype than in CC genotype (P <
0.01). The ratio of ApoA-I to ApoB in drinkers was
lower in GG genotype than in CC or CG genotype (P <
0.01 for each).
Serum TC, TG, HDL-C and ApoA-I levels in CC gen-
otype, TC, HDL-C, ApoA-I levels and the ratio of
ApoA-I to ApoB in CG genotype, and TC, TG, LDL-C,
ApoA-I and ApoB levels in GG genotype were higher in
Table 1 Comparison of the general characteristics and serum lipid levels between the nondrinkers and drinkers
Parameter Nondrinker
(n = 516)
Drinker
(n = 514)
t (c
2) P
Male/female 186/330 306/208 56.930 0.000
Age (years) 41.26 ± 19.53 45.35 ± 15.38 -3.733 0.000
Body mass index (kg/m
2) 21.66 ± 2.71 21.95 ± 2.39 -1.821 0.069
Systolic blood pressure (mmHg) 120.03 ± 16.15 125.60 ± 15.63 -5.624 0.000
Diastolic blood pressure (mmHg) 74.13 ± 9.82 77.79 ± 9.78 -5.993 0.000
Pulse pressure (mmHg) 45.95 ± 11.89 47.83 ± 12.01 -2.525 0.012
Cigarette smoking [n(%)]
Nonsmoker 414(80.2) 292(56.8)
<20 cigarettes/day 62(12.0) 106(20.6)
≥20 cigarettes/day 40(7.8) 116(22.6) 69.628 0.000
Alcohol consumption [n(%)]
Nondrinker 516(100.0) -
<25 g/day - 396(77.0)
≥25 g/day - 118(23.0)
Total cholesterol (mmol/L) 4.52 ± 0.99 4.65 ± 0.95 -2.150 0.032
Triglyceride (mmol/L)
a 0.97 ± 0.57 1.00 ± 0.61 -2.488 0.013
HDL-C (mmol/L) 1.98 ± 0.45 2.14 ± 0.49 -5.458 0.000
LDL-C (mmol/L) 2.40 ± 0.70 2.41 ± 0.70 -0.229 0.819
Apolipoprotein (Apo) A-I (g/L) 1.40 ± 0.16 1.48 ± 0.13 -8.805 0.000
ApoB (g/L) 0.89 ± 0.22 0.92 ± 0.20 -2.290 0.022
ApoA-I/ApoB 1.68 ± 0.57 1.69 ± 0.46 -0.310 0.757
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
aThe value of TG was presented as median (interquartile range). The
difference between the two ethnic groups was determined by the Wilcoxon-Mann-Whitney test.
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Page 4 of 10Figure 1 Genotyping of PCR products of the samples. Lane M, 100 bp Marker Ladder; Lanes 1 and 2, the PCR products of the samples (596
bp); Lane 3 and 4, CC genotype (596 bp); Lanes 5 and 6, CG genotype (596 bp, 371 bp and 225 bp); and lanes 7 and 8, GG genotype (371 bp
and 225 bp).
Figure 2 A part of the nucleotide sequence of the ApoC-III 3238C>G. (A) CC genotype; (B) CG genotype; (C) GG genotype.
Ruixing et al. Lipids in Health and Disease 2010, 9:86
http://www.lipidworld.com/content/9/1/86
Page 5 of 10drinkers than in nondrinkers (P < 0.05-0.01). But the
r a t i oo fA p o A - It oA p o Bi nG Gg e n o t y p ew a sl o w e ri n
drinkers than in nondrinkers (P < 0.01).
Correlation between genotype and serum lipid
parameters
Multivariate logistic regression analysis showed that the
levels of TC, TG LDL-C and ApoA-I were correlated
with genotype in the combined population (P < 0.05-
0.01). The levels of TC, TG and ApoB were correlated
with genotype in nondrinkers (P <0 . 0 5f o ra l l ) .T h e
levels of TC, LDL-C and ApoB were associated with
genotype in drinkers (P < 0.01 for all). Serum lipid para-
meters were also correlated with age, sex, alcohol con-
sumption, cigarette smoking, blood pressure, body
weight, and BMI in both nondrinkers and drinkers
(Table 4).
Discussion
The results of the present study show that the levels of
TC, TG, HDL-C, ApoA-I and ApoB were higher in
drinkers than in nondrinkers. There was no significant
difference in the levels of LDL-C and the ratio of ApoA-
I to ApoB between the two groups. These findings are
consistent with those of several previous studies. A
moderate intake of alcohol is associated with protection
against CAD, probably due in part to a dose-dependent
increase in HDL-C [65,66]. According to Rimma et al.
[67], a daily dose of 30 g alcohol results in an average
HDL level rise of 3.99 mg/dl, and an ApoA-I level rise
of 8.82 mg/dl. Alcohol also causes an increase of TG
lipase activity and a decrease of the HDL removal from
the circulation [68]. A decrease in LDL-C with increased
alcohol intake has also been reported in some studies,
but this effect is less consistent and probably depends
on the combination of one or more unmeasured factors
[68].
The present study shows that there was no significant
difference in the allelic and genotypic frequencies of the
ApoC-III 3238C>G between the nondrinkers and drin-
kers. The frequency of G allele was 32.8% in nondrin-
kers, and 32.1% in drinkers, which is quite similar to the
results in Taiwanese (0.30-0.43) [46,69], Japanese (0.25-
0.48) [70], and Indians (0.36) [27], but is higher than
those reported for Caucasians in whom the G allele fre-
quency was 0.00-0.11 [27,55]. These results suggest that
there exists significant racial variation of allele frequen-
cies in this locus.
The relationship between the ApoC-III 3238C>G poly-
morphism and plasma or serum lipid levels in humans
has been evaluated in a large number of studies. How-
ever, previous findings on the association of this poly-
morphism with the changes in plasma lipid levels are
inconsistent [71-73]. Previous cohort studies, as well as
case-control and familial studies have shown significant
association between the rare allele of the polymorphic
SstI site (3238G) and higher plasma TG levels [16-53]
and CAD [53-62]. This association has been reported in
studies carried out with Caucasians, Chinese, Mayans,
Japanese (living in Japan or living in Southern Brazil),
Koreans, Arabs, and Asian Indians [27,49,55,69,70].
However, several reports failed to find a significant
Table 2 Genotypic and allelic frequencies between the
nondrinkers and drinkers [n (%)]
Group n Genotype Allele
CC CG GG C G
Nondrinker 516 236(45.7) 222(43.0) 58(11.3) 694(67.2) 338(32.8)
Drinker 514 232(45.2) 234(45.5) 48(9.3) 698(67.9) 330(32.1)
c
2 - 1.290 0.010
P - 0.525 0.752
Table 3 Comparison of serum lipid levels among the genotypes and between the nondrinkers and drinkers
Group Genotype n TC
(mmol/L)
TG
(mmol/L)
HDL-C
(mmol/L)
LDL-C
(mmol/L)
ApoA-I
(g/L)
ApoB
(g/L)
ApoA-I/
ApoB
Nondrinker CC 236 4.49 ± 0.88 0.91 ± 0.57 1.97 ± 0.42 2.41 ± 0.69 1.40 ± 0.13 0.89 ± 0.21 1.70 ± 0.64
CG 222 4.53 ± 1.11 1.01 ± 0.59
b 1.98 ± 0.48 2.40 ± 0.68 1.40 ± 0.18 0.91 ± 0.22 1.62 ± 0.41
GG 58 4.57 ± 1.03 0.93 ± 0.60 2.01 ± 0.43 2.40 ± 0.83 1.42 ± 0.12 0.86 ± 0.28 1.84 ± 0.75
c
F - - 0.186 12.517 0.187 0.013 0.445 1.275 3.685
P - - 0.830 0.002 0.829 0.987 0.641 0.280 0.026
Drinker CC 232 4.72 ± 0.90** 0.97 ± 0.63** 2.07 ± 0.45* 2.38 ± 0.71 1.47 ± 0.14** 0.91 ± 0.20 1.70 ± 0.46
CG 234 4.75 ± 0.86* 0.95 ± 0.54 2.23 ± 0.53
b** 2.37 ± 0.66 1.49 ± 0.13** 0.91 ± 0.20 1.73 ± 0.47**
GG 48 5.29 ± 0.91
bd** 1.28 ± 0.93
bd** 2.12 ± 0.49 2.77 ± 0.72
bd* 1.49 ± 0.14** 1.06 ± 0.18
bd** 1.44 ± 0.30
bd**
F - - 8.662 18.352 6.253 7.173 1.382 12.457 8.300
P - - 0.000 0.000 0.002 0.000 0.252 0.000 0.000
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA-I, apolipoprotein A-I; ApoB,
apolipoprotein B. The value of TG was presented as median (interquartile range). The difference among the genotypes was determined by the Kruskal-Wallis test.
aP <0 . 0 5a n d
bP < 0.01 in comparison with CC genotype of the same subgroup;
cP < 0.05 and
dP < 0.01 in comparison with CG genotype of the same subgroup;
*P <0 . 0 5a n d* * P < 0.01 in comparison with the same subgroup of the nondrinkers.
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Lipid parameter Risk factor Odds ratio c
2 P 95% CI
Nondrinkers plus drinkers
TC Age 1.030 45.053 0.000 1.021-1.039
Body mass index 1.144 22.000 0.000 1.081-1.210
ApoC-III 3238C>G genotype 1.324 6.542 0.011 1.068-1.642
TG Body mass index 1.223 30.735 0.000 1.139-1.314
Pulse pressure 1.018 5.255 0.022 1.003-1.034
Alcohol consumption 1.744 14.249 0.000 1.307-2.329
Cigarette smoking 0.614 4.056 0.044 0.382-0.987
ApoC-III 3238C>G genotype 1.517 8.448 0.004 1.145-2.009
LDL-C Age 1.030 14.365 0.000 1.014-1.046
Sex 1.898 5.549 0.018 1.114-3.236
Body weight 1.107 43.419 0.000 1.074-1.141
Alcohol consumption 0.704 4.248 0.039 0.504-0.983
ApoC-III 3238C>G genotype 1.709 9.600 0.002 1.218-2.400
ApoA-I Age 0.745 12.294 0.000 0.632-0.878
Sex 0.414 9.812 0.002 0.238-0.719
Pulse pressure 0.974 4.009 0.045 0.949-0.999
Alcohol consumption 0.327 12.749 0.000 0.177-0.604
ApoB Age 1.036 38.386 0.000 1.025-1.048
Body weight 1.086 45.102 0.000 1.060-1.113
Alcohol consumption 3.154 7.351 0.007 1.375-7.234
ApoC-III 3238C>G genotype 1.678 15.923 0.000 1.301-2.163
Sex 1.678 3.923 0.048 1.004-2.219
Nondrinkers
TC Age 1.142 13.511 0.000 1.064-1.225
Body mass index 1.175 14.633 0.000 1.082-1.277
ApoC-III 3238C>G genotype 1.324 6.542 0.011 1.068-1.642
Cigarette smoking 0.639 4.668 0.031 0.425-0.959
TG Body mass index 1.163 7.954 0.005 1.047-1.292
Age 1.314 9.279 0.002 1.102-1.566
Cigarette smoking 0.280 5.302 0.021 0.095-0.827
ApoC-III 3238C>G genotype 2.200 12.048 0.044 1.410-3.434
LDL-C Age 1.039 13.847 0.000 1.018-1.060
Body weight 1.131 34.897 0.000 1.086-1.178
Sex 3.379 9.542 0.002 1.561-7.317
ApoA-I Body weight 1.061 4.339 0.037 1.004-1.122
Body mass index 0.671 14.044 0.000 0.545-0.827
Age 0.733 11.783 0.001 0.614-0.875
Cigarette smoking 1.667 4.219 0.040 1.024-2.713
ApoB Age 1.143 11.084 0.001 1.057-1.237
Body weight 1.084 25.440 0.000 1.051-1.119
ApoC-III 3238C>G genotype 1.574 6.223 0.013 1.102-2.248
Drinkers
TC Age 1.326 15.892 0.000 1.154-1.523
Body weight 1.052 12.961 0.000 1.023-1.082
ApoC-III 3238C>G genotype 1.874 16.157 0.000 1.380-2.545
TG Alcohol consumption 0.674 10.599 0.001 0.532-0.855
Body mass index 1.270 23.776 0.000 1.154-1.399
LDL-C Height 1.063 7.372 0.007 1.017-1.112
ApoC-III 3238C>G genotype 2.319 10.577 0.001 1.397-3.849
ApoA-I Body weight 1.078 6.384 0.037 1.017-1.143
Systolic blood pressure 0.942 7.787 0.005 0.903-0.982
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vious work, Kee and coworkers found no association
between variability at the SstI ApoC-III gene site (in the
3%-noncoding region) and lipid, lipoproteins and com-
plex lipoprotein particles in a sample of men from
northern France [72]. They thought that the SstIp o l y -
morphism is not major contributors to the risk of dysli-
pidemia in the population of northern France. Results
from the current study are consistent with many studies
cited above which reported associations of ApoC-III
gene polymorphism with altered lipid metabolism. The
levels of TG in nondrinkers were higher in CG genotype
than in CC genotype, and the ratio of ApoA-I to ApoB
in nondrinkers was higher in GG genotype than in CG
genotype. The levels of TC, TG, LDL-C and ApoB in
drinkers were higher in GG genotype than in CC or CG
genotype. The levels of HDL-C in drinkers were higher
in CG genotype than in CC genotype. The ratio of
ApoA-I to ApoB in drinkers was lower in GG genotype
than in CC or CG genotype.
The interactions of the ApoC-III 3238C>G poly-
morphism and alcohol consumption on serum lipid
levels are not well known. In the present study, we
showed that serum TC, TG, HDL-C and ApoA-I levels
in CC genotype, TC, HDL-C, ApoA-I levels and the
ratio of ApoA-I to ApoB in CG genotype, and TC, TG,
LDL-C, ApoA-I and ApoB levels in GG genotype were
higher in drinkers than in nondrinkers. But the ratio of
ApoA-I to ApoB in GG genotype was lower in drinkers
than in nondrinkers. The levels of TG were correlated
with genotype in nondrinkers, whereas the levels of TG
were positively associated with alcohol consumption in
drinkers. These findings suggest that the ApoC-III
3238CG heterozygotes benefited more from alcohol
consumption than CC and GG homozygotes in increas-
ing serum levels of HDL-C, ApoA-I, and the ratio of
ApoA-I to ApoB, and lowering serum levels of TC and
TG. The effect of different kinds of wine on the lipid
profiles is not well known. In a previous study, Ruida-
vets et al. [74] found that wine was positively associated
with HDL-C. Beer was positively associated with HDL-C
in men and with TGs in men and women. When taking
drinking patterns into account, wine drinkers had higher
HDL-C levels than non-wine drinkers. In another study,
Choudhury et al. [75] also showed serum TGs levels
were significantly lower in those who drank beer. Thus,
we hypothesize that the interactions between the ApoC-
III 3238C>G polymorphism and different kinds of alco-
holic beverage on serum lipid levels may be different.
Conclusion
The results of the present study show that there was no
significant difference in genotypic and allelic frequencies
of the ApoC-III 3238C>G polymorphism between the
nondrinkers and drinkers. But the interactions of the
ApoC-III 3238C>G polymorphism and alcohol con-
sumption on serum lipid levels are different among the
three genotypes. The ApoC-III 3238CG heterozygotes
benefited more from alcohol consumption than CC and
GG homozygotes in increasing serum levels of HDL-C,
ApoA-I, and the ratio of ApoA-I to ApoB, and lowering
serum levels of TC and TG.
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